Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles.

Lötvall, J; Hill, Andrew; Hochberg, F; Buzás, EI; Di Vizio, D; Gardiner, C; Gho, YS; Kurochkin, IV; Mathivanan, Suresh; Quesenberry, P; Sahoo, S; Tahara, H; Wauben, MH; Witwer, KW; Théry, C

doi:10.26181/19491671.v1

Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles.

journal contribution

posted on 2022-03-31, 22:15 authored by J Lötvall, Andrew HillAndrew Hill, F Hochberg, EI Buzás, D Di Vizio, C Gardiner, YS Gho, IV Kurochkin, Suresh MathivananSuresh Mathivanan, P Quesenberry, S Sahoo, H Tahara, MH Wauben, KW Witwer, C Théry

Secreted membrane-enclosed vesicles, collectively called extracellular vesicles (EVs), which include exosomes, ectosomes, microvesicles, microparticles, apoptotic bodies and other EV subsets, encompass a very rapidly growing scientific field in biology and medicine. Importantly, it is currently technically challenging to obtain a totally pure EV fraction free from non-vesicular components for functional studies, and therefore there is a need to establish guidelines for analyses of these vesicles and reporting of scientific studies on EV biology. Here, the International Society for Extracellular Vesicles (ISEV) provides researchers with a minimal set of biochemical, biophysical and functional standards that should be used to attribute any specific biological cargo or functions to EVs.

Funding

JL: Co-owner of patents from 2006 to 2012 (approved and pending) for using exosomes as therapeutics. AFH: Co-owner of patent (pending) for using exosomal miRNA as a biomarker; shareholder in D-Gen Ltd. DDV: Inventor of 2 patents on EVs as circulating biomarkers of cancer (pending). YSG: Inventor of patents for using EVs as therapeutics, diagnostics and vaccines; founder of Aeon Medix and own stock in the company; sponsored research agreements with AmorePacific. IK: Co-inventor of a technology for purification of exosomes licensed to Cell Guidance Systems Ltd that uses it for manufacturing Exo-spinTM kits. SS: Co-inventor of a patent (pending) on the use of exosomes as therapeutics in cardiovascular diseases. Sponsored research agreements with Baxter Healthcare and NeoStem. HT: Founder of MiRTeL, and own stock in the company. MHW: Collaborative research agreement with Friesland Campina on bovine milk EVs and with BD Biosciences on high resolution flow cytometry of EVs, and partnership between Technology Foundation STW, Utrecht University and Danone Nutricia research on EV-based biomarker profiling in human breast milk. KWW: Scientific research agreement with AgriSciX, Inc. Other authors declare no significant relationships or conflicts.

History

Publication Date

2014-01-01

Journal

Journal of extracellular vesicles

Volume

3

Issue

1

Article Number

26913

Pagination

6p. (p. 1-6)

Publisher

Co-Action Publishing

ISSN

2001-3078

Rights Statement

© 2014 Jan Lötvall et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.